401790-95-2Relevant academic research and scientific papers
Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis
Wang, Minmin,Winneroski, Leonard L.,Ardecky, Robert J.,Babine, Robert E.,Brooks, Dawn A.,Etgen, Garret J.,Hutchison, Darrell R.,Kauffman, Raymond F.,Kunkel, Aaron,Mais, Dale E.,Montrose-Rafizadeh, Chahrzad,Ogilvie, Kathleen M.,Oldham, Brian A.,Peters, Mary K.,Rito, Christopher J.,Rungta, Deepa K.,Tripp, Allie E.,Wilson, Sarah B.,Xu, Yanping,Zink, Richard W.,McCarthy, James R.
, p. 6113 - 6116 (2007/10/03)
To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.
Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/ γ Agonists
Xu, Yanping,Rito, Christopher J.,Etgen, Garret J.,Ardecky, Robert J.,Bean, James S.,Bensch, William R.,Bosley, Jacob R.,Broderick, Carol L.,Brooks, Dawn A.,Dominianni, Samuel J.,Hahn, Patric J.,Liu, Sha,Mais, Dale E.,Montrose-Rafizadeh, Chahrzad,Ogilvie, Kathy M.,Oldham, Brian A.,Peters, Mary,Rungta, Deepa K.,Shuker, Anthony J.,Stephenson, Gregory A.,Tripp, Allie E.,Wilson, Sarah B.,Winneroski, Leonard L.,Zink, Richard,Kauffman, Raymond F.,McCarthy, James R.
, p. 2422 - 2425 (2007/10/03)
The design and synthesis of the dual peroxisome proliferator activated receptor (PPAR) α/γ agonist (S)-2-methyl-3-{4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)ethoxy]phenyl} -2-phenoxypropionic acid (2) for the treatment of type 2 diabetes and associated d
Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
-
, (2008/06/13)
Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
